Relapses and Recurrences in Giant Cell Arteritis: A Population-Based Study of Patients With Biopsy-Proven Disease From Northwestern Spain

We conducted the present study to determine the incidence of disease flares (relapses and recurrences) in a series of patients with biopsy-proven giant cell arteritis (GCA). We assessed a series of 174 patients who were diagnosed with biopsy-proven GCA, uniformly treated, and followed at the rheumatology division of Hospital Xeral-Calde (Lugo, Spain), the single rheumatology division for a well-defined population. All of them were followed for at least 1 year after the disease diagnosis. Seventy-one (40.8%) experienced relapses or recurrences of the disease. Patients who had relapses or recurrences did not show clinical differences when compared with the remaining biopsy-proven GCA patients. However, the total duration of corticosteroid therapy was significantly longer in those patients who had relapses or recurrences of the disease. The median dose of prednisone and the median duration of corticosteroid treatment at the time of the first relapse were 5 mg/d and 16 months, respectively. Headache (52%) was the most common feature at the time of the first relapse. Polymyalgia rheumatica manifestations occurred in 30% of the patients at that time. However, none of them developed visual loss. Thirty-two patients experienced recurrences of the disease when prednisone dose had been discontinued. The median time from the disease diagnosis to the time of the recurrence was 23 months. The presence of anemia (hemoglobin <12 g/dL) at the time of disease diagnosis was the best predictor of relapses or recurrences of GCA (odds ratio, 2.17; 95% confidence interval, 1.02-4.62; p = 0.04). The results from the present study confirm that relapses and recurrences are frequent in homogenously treated patients with biopsy-proven GCA. A chronic inflammatory response manifested by anemia at the time of disease diagnosis may predict the development of disease flares.Abbreviations: CI = confidence interval, ESR = erythrocyte sedimentation rate, GCA = giant cell arteritis, IL = interleukin, IQR = interquartile range, OR = odds ratio, PMR = polymyalgia rheumatica, SD = standard deviation.

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[2]  Javier Martín,et al.  Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.

[3]  O. Steichen,et al.  Comment on: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis: reply , 2009 .

[4]  M. González-Gay,et al.  Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis , 2009, Medicine.

[5]  B. Bengtsson,et al.  Long-term corticosteroid treatment in giant cell arteritis. , 2009, Acta medica Scandinavica.

[6]  Javier Martín,et al.  Systemic Sclerosis in Northwestern Spain: A 19-year Epidemiologic Study , 2008, Medicine.

[7]  M. Sonnenblick,et al.  Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. , 2008, Clinical and experimental rheumatology.

[8]  Javier Martín,et al.  Giant Cell Arteritis in Northwestern Spain: A 25-Year Epidemiologic Study , 2007, Medicine.

[9]  Javier Martín,et al.  Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. , 2006, Medicine.

[10]  M. González-Gay,et al.  Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. , 2006, Medicine.

[11]  G. Hunder,et al.  Aortic Aneurysm and Dissection in Patients With Biopsy-Proven Giant Cell Arteritis From Northwestern Spain: A Population-Based Study , 2004, Medicine.

[12]  M. González-Gay,et al.  Influence of Traditional Risk Factors of Atherosclerosis in the Development of Severe Ischemic Complications in Giant Cell Arteritis , 2004, Medicine.

[13]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[14]  G. Hunder,et al.  Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. , 2003, Arthritis and rheumatism.

[15]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[16]  W. Ollier,et al.  Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. , 2003, Seminars in arthritis and rheumatism.

[17]  H. Kleinman,et al.  Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis , 2002, Circulation.

[18]  D. Hellmann.  Temporal arteritis: a cough, toothache, and tongue infarction. , 2002, JAMA.

[19]  J. Fernandez-Solà,et al.  A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. , 2002, Arthritis and rheumatism.

[20]  R. Tomsak.  Giant cell arteritis. , 2002, Ophthalmology.

[21]  T. Wilsgaard,et al.  Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. , 2001, Rheumatology.

[22]  E. Hachulla,et al.  Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. , 2001, Clinical and experimental rheumatology.

[23]  M. González-Gay,et al.  Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. , 2001, Seminars in arthritis and rheumatism.

[24]  A. Hajeer,et al.  Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients , 2000, Medicine.

[25]  R. Pujol,et al.  Erythema nodosum: etiologic and predictive factors in a defined population. , 2000, Arthritis and rheumatism.

[26]  M. Gonzalez-gay,et al.  Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. , 1999, Medicine.

[27]  W. Ollier,et al.  The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. , 1999, The Journal of rheumatology.

[28]  M. Gonzalez-gay,et al.  Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. , 1998, The Journal of rheumatology.

[29]  D. Ibañez,et al.  Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. , 1997, The Journal of rheumatology.

[30]  G. Hunder,et al.  Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. , 1996, The American journal of medicine.

[31]  G. Hoffman,et al.  Treatment of corticosteroid-resistant giant cell arteritis. , 1995, Rheumatic diseases clinics of North America.

[32]  M. González-Gay,et al.  Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients. , 1992, The Journal of rheumatology.

[33]  I. Lundberg,et al.  Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. , 1990, The Journal of rheumatology.

[34]  P. Joly,et al.  Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). , 1988, Annals of the rheumatic diseases.

[35]  R. Caselli,et al.  Neurologic disease in biopsy‐proven giant cell (temporal) arteritis , 1988, Neurology.

[36]  L. A. Healey,et al.  Polymyalgia rheumatica and giant cell arteritis. , 1984, Western Journal of Medicine.

[37]  L. A. Healey,et al.  Presentation of occult giant cell arteritis. , 1980, Arthritis and rheumatism.

[38]  D. Formisano,et al.  Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. , 2009, Rheumatology.

[39]  A. de la Sierra,et al.  Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. , 1998, Arthritis and rheumatism.